☆ 4.7 Review

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

EUROPEAN JOURNAL OF CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

添加到收藏夹

Editorial Material Oncology

Emerging issues related to COVID-19 vaccination in patients with cancer

Kamal S. Saini et al.

Summary: COVID-19 has had a severe impact on oncology care and research, with the rollout of vaccines raising hopes of controlling the pandemic. However, new issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants also need to be addressed.

ONCOLOGY AND THERAPY (2021)

添加到收藏夹

Article Oncology

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Antoni Ribas et al.

Summary: Patients with cancer, especially those with hematologic malignancies, are considered among the very high-risk groups for priority COVID-19 vaccination due to the confluence of risk factors between cancer and the virus, which may increase exposure and suppress immune responses.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Sjoukje F. Oosting et al.

Summary: This study aimed to evaluate the immunogenicity and safety of the mRNA-1273 COVID-19 vaccine for patients with solid tumours receiving systemic cancer treatment. The majority of patients developed an adequate antibody response after two vaccinations, indicating the vaccine is safe in these patients. Some patients with an inadequate response may benefit from a third vaccination.

LANCET ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

R. Palich et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey

J. Barriere et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

J. Barriere et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

添加到收藏夹

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al.

Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Sarah Bird et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib

Paola Guglielmelli et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

William A. Werbel et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Letter Oncology

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

P. Heudel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington et al.

Summary: This study found that most patients with CML developed antibodies and polyfunctional T-cell responses after receiving a single dose of the SARS-CoV-2 BNT162b2 vaccine, demonstrating good immunogenicity in this patient population compared to those with solid tumors or lymphoid hematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients

Magdalena Benda et al.

Summary: The study evaluated the serological response, predictive markers, and safety of BNT162b2 in haemato-oncological patients. Results showed that over 70% of oncological patients and around 70% of haematological patients developed antibodies after vaccination, with some patients at risk of serological non-response. Vaccination was well tolerated with low risk of severe side effects.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Hematology

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Onima Chowdhury et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient

Joshua A. Hill et al.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Editorial Material Oncology

Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution

Elizabeth A. Griffiths et al.

Summary: SARS-CoV-2 vaccines are effective in preventing severe COVID-19, especially for cancer patients. Studies in Cancer Cell reveal the heterogeneity of immune responses to vaccination among cancer patients, highlighting the need for further research in this area.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience

Gabriel Revon-Riviere et al.

Summary: The study evaluated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with solid tumors, showing good tolerability and effectiveness in preventing COVID-19 infection in this population. Additional monitoring is needed to confirm these preliminary results and determine long-term vaccination effectiveness.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Cengiz Karacin et al.

Summary: The study evaluated the immunogenicity and safety of the CoronaVac vaccine in cancer patients receiving active systemic therapy, with an immunogenicity rate of 63.8%. Patients receiving monoclonal antibody or immunotherapy alone had a 100% immunogenicity rate.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Ilies Benotmane et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Letter Oncology

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Fulvia Pimpinelli et al.

Summary: Among 42 Philadelphia negative myeloproliferative neoplasm patients receiving systemic active treatment, those with myelofibrosis showed significantly lower response to the anti-SARS-CoV-2 BNT162b2 vaccine compared to patients with essential thrombocythemia and polycythemia vera in terms of IgG titers and seroprotection rates. The ongoing treatment with Ruxolitinib in some patients may be associated with reduced vaccine immunogenicity, but further large prospective studies are needed to confirm this finding.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Tina Schmidt et al.

Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

A French cohort for assessing COVID-19 vaccine responses in specific populations

Paul Loubet et al.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Johan Normark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Letter Oncology

Attitudes and Factors Associated With COVID-19 Vaccine Hesitancy Among Patients With Breast Cancer

Cynthia Villarreal-Garza et al.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh et al.

Summary: The study showed that 90% of patients with cancer undergoing treatment had an adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research is needed to explore the clinical relevance and durability of these lower titers.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Tal Goshen-Lago et al.

Summary: This study aimed to evaluate the safety of BNT162b2 vaccine in patients undergoing cancer treatment. The results showed most cancer patients achieved seroconversion after the second dose of the vaccine, but at a slower rate compared to non-cancer controls. Future real-world data are needed to determine the long-term efficacy of the vaccine in different types of cancer treatments.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+B-Lymphocyte Count and Anti-CD38 Treatment

Susanne Ghandili et al.

Summary: The global impact of the COVID-19 pandemic has prompted rapid development of multiple anti-SARS-CoV-2 vaccines. Data on the efficacy of these vaccines in patients with hematological malignancies, especially plasma cell neoplasia, are limited. An observational study of 82 patients with multiple myeloma and related plasma cell neoplasia found that 23% had positive SARS-CoV-2 spike protein antibody titers after the first vaccination. Higher CD19+ B lymphocyte counts and treatment with anti-CD38 antibodies were associated with significantly higher antibody titers, while older age and poorly controlled disease correlated negatively with antibody levels. Majorities of these patients may require booster vaccinations due to poor initial response.

CANCERS (2021)

添加到收藏夹

Editorial Material Oncology

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Wenhua Liang et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

Evandro de Azambuja et al.

ESMO OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.